Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) EPS (Weighted Average and Diluted) (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed EPS (Weighted Average and Diluted) for 9 consecutive years, with -$0.04 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 90.48% to -$0.04 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.85 through Dec 2025, up 29.17% year-over-year, with the annual reading at -$0.79 for FY2025, 33.61% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.04 at Marker Therapeutics, up from -$0.12 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.76 in Q4 2022, with the low at -$5.04 in Q4 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.51, with a median of -$0.28 recorded in 2025.
  • The sharpest move saw EPS (Weighted Average and Diluted) plummeted 2686.82% in 2021, then skyrocketed 146.03% in 2023.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$5.04 in 2021, then surged by 115.08% to $0.76 in 2022, then crashed by 139.47% to -$0.3 in 2023, then crashed by 40.0% to -$0.42 in 2024, then skyrocketed by 90.48% to -$0.04 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.04, -$0.12, and -$0.29 for Q4 2025, Q3 2025, and Q2 2025 respectively.